Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821303 | 0.91 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL29354115 | 0.91 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL27499 | 0.91 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7058506 | 0.90 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.90 | ESR1 (0.91) | ESR1ESR2 | |
| SCHEMBL7056839 | 0.88 | ESR1 (0.94) | ESR1ESR2 | |
| SCHEMBL28107129 | 0.85 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL12035602 | 0.84 | ESR1 (0.80) | ESR1ESR2 | |
| SCHEMBL6259524 | 0.83 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL2898159 | 0.83 | ESR1 (0.84) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| US-10478443-B2 | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women | ENDORECHERCHE, INC. (CA) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885 |
| US-10478443-B2 | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women | GPER1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.